Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 114

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 114
---
, 2023)10.1Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 2025 (incorporated by reference from Exhibit 10.1 of the Company’s Form 10-Q filed on May 12, 2025)10.2Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 2025 (incorporated by reference from Exhibit 10.2 of the Company’s Form 10-Q filed on May 12, 2025)10.3Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 2025 (incorporated by reference from Exhibit 10.3 of the Company’s Form 10-Q filed on May 12, 2025)10.4Severance and Change of Control Agreement by and between Company and James Hamilton, dated May 8, 2025 (incorporated by reference from Exhibit 10.4 of the Company’s Form 10-Q filed on May 12, 2025)10.5CFO Retirement Letter by and between Company and Ken Myszkowski, dated May 9, 2025 (incorporated by reference from Exhibit 10.5 of the Company’s Form 10-Q filed on May 12, 2025)10.6*Amendment No. 12 to Lease Agreement by and between Arrowhead Madison, Inc. and University Research Park, dated June 11, 202531.1*Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2*Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1**Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2**Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Ox